SCHEMBL16469731

SCHEMBL16469731

COC(=O)c1c(F)cc(NS(=O)(=O)c2ccc(Cl)nc2)cc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.58
MAPK1 P28482 2/20 0.58
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 4/20 0.47
GAA P10253 2/20 0.46
HSD17B1 P14061 2/20 0.46
HSD17B2 P37059 2/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
PABPC1 P11940 1/20 0.46
HTT P42858 3/20 0.44
NR2F2 P24468 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CCR2 P41597 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
KCNQ3 O43525 1/20 0.41
KCNQ2 O43526 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15360020 0.83 KDM4E (0.51) LMNAMAPK1KDM4EALDH1A1GAA
SCHEMBL16469306 0.79 ALDH1A1 (0.52) LMNAKDM4EALDH1A1MEN1KMT2A
SCHEMBL16470520 0.79 NHERF1 (0.51) LMNAKDM4EALDH1A1HSD17B2MAPT
SCHEMBL16469850 0.79 KDM4E (0.49) LMNAKDM4EALDH1A1GAAHTT
SCHEMBL24312124 0.78 FFAR4 (0.54) KDM4EALDH1A1GAAMEN1KMT2A
SCHEMBL16529720 0.78 ALDH1A1 (0.53) LMNAMAPK1KDM4EALDH1A1GAA
SCHEMBL16469750 0.78 CA12 (0.51) KDM4EALDH1A1GAAMEN1KMT2A
SCHEMBL28058154 0.77 TDP1 (0.62) LMNAMAPK1KDM4EALDH1A1MEN1
SCHEMBL16489168 0.77 KDM4E (0.47) LMNAKDM4EALDH1A1GAAHTT
SCHEMBL16470170 0.75 MAPT (0.48) LMNAKDM4EALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9533985-B2 Sulfonamide derivative and medicinal use thereof EA PHARMA CO., LTD. (JP) 2017-01-03 US disclosed
US-9533985-B2 Sulfonamide derivative and medicinal use thereof EA PHARMA CO., LTD. (JP) 2017-01-03 US disclosed
CN-104395297-B Sulfonamide derivatives and pharmaceutical use thereof AJINOMOTO CO.,INC. (JP) 2016-05-04 CN disclosed
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF AJINOMOTO CO., LTD. (JP) 2015-02-19 US disclosed
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF AJINOMOTO CO., LTD. (JP) 2015-02-19 US disclosed
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF AJINOMOTO CO., LTD. (JP) 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF ITGB4, ITGA4, ITGA2 LMNA 4178/4885MAPK1 3932/4885KDM4E 771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.